TY - JOUR
T1 - Protein Phosphatase 1-Targeting Small-Molecule C31 Inhibits Ebola Virus Replication
AU - Ammosova, Tatiana
AU - Pietzsch, Colette A.
AU - Saygideǧer, Yasemin
AU - Ilatovsky, Andrey
AU - Lin, Xionghao
AU - Ivanov, Andrey
AU - Kumari, Namita
AU - Jerebtsova, Marina
AU - Kulkarni, Amol
AU - Petukhov, Michael
AU - Üren, Aykut
AU - Bukreyev, Alexander
AU - Nekhai, Sergei
N1 - Publisher Copyright:
© 2018. This article contains public sector information licensed under the Open Government Licence v3.0.
PY - 2018/11/22
Y1 - 2018/11/22
N2 - Ebola virus (EBOV) infection causes severe hemorrhagic fever. EBOV transcription is controlled by host protein phosphatase 1 (PP1), which dephosphorylates VP30 protein. We previously developed 1E7-03, a compound targeting a noncatalytic site of PP1 that induced VP30 phosphorylation and inhibited EBOV transcription. Here, we attempted to further improve 1E7-03, which was not stable in murine serum. Results. High-throughput screening with EBOV-green fluorescent protein was conducted on 72 1E7-03 analogs and identified 6 best inhibitory and the least toxic compounds. A parallel in silico screening of compounds from the ZINC database by docking to PP1 identified the best-binding compound C31, which was also present among the top 6 compounds found in the viral screen. C31 showed the best EBOV inhibitory activity among the top 6 compounds and also inhibited EBOV minigenome. C31 bound to the PP1 C-terminal groove in vitro and increased VP30 phosphorylation in cultured cells. C31 demonstrated improved stability in mouse plasma and cell permeability, compared with 1E7-03. It was also detected for 24 hours after injection in mice. Conclusion. C31 represents a novel PP1-targeting EBOV inhibitor with improved pharmacological properties that can be further evaluated for future antifiloviral therapy.
AB - Ebola virus (EBOV) infection causes severe hemorrhagic fever. EBOV transcription is controlled by host protein phosphatase 1 (PP1), which dephosphorylates VP30 protein. We previously developed 1E7-03, a compound targeting a noncatalytic site of PP1 that induced VP30 phosphorylation and inhibited EBOV transcription. Here, we attempted to further improve 1E7-03, which was not stable in murine serum. Results. High-throughput screening with EBOV-green fluorescent protein was conducted on 72 1E7-03 analogs and identified 6 best inhibitory and the least toxic compounds. A parallel in silico screening of compounds from the ZINC database by docking to PP1 identified the best-binding compound C31, which was also present among the top 6 compounds found in the viral screen. C31 showed the best EBOV inhibitory activity among the top 6 compounds and also inhibited EBOV minigenome. C31 bound to the PP1 C-terminal groove in vitro and increased VP30 phosphorylation in cultured cells. C31 demonstrated improved stability in mouse plasma and cell permeability, compared with 1E7-03. It was also detected for 24 hours after injection in mice. Conclusion. C31 represents a novel PP1-targeting EBOV inhibitor with improved pharmacological properties that can be further evaluated for future antifiloviral therapy.
KW - Ebola virus
KW - protein phosphatase 1
KW - transcription inhibitor.
UR - http://www.scopus.com/inward/record.url?scp=85057155054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057155054&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiy422
DO - 10.1093/infdis/jiy422
M3 - Article
C2 - 30169869
AN - SCOPUS:85057155054
SN - 0022-1899
VL - 218
SP - S627-S635
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -